Positive topline results from the phase 2a HERALD study of ALG-055009 in MASH highlight the THR-β agonist’s impact on liver fat reduction.

EDG-7500 was well-tolerated in healthy patients in Phase 1 while achieving gradient relief without LVEF reductions in the Phase 2 CIRRUS-HCM trial.

Panelists discuss how continued cycling of tumor necrosis factor inhibitors (TNFis) without achieving remission can lead to complications like irreversible joint erosion, significantly diminishing patient quality of life, and explore why providers may persist with TNFis despite failure, access barriers to switching mechanisms of action, and treatment considerations for patients whose initial positive response to TNFis declines over time.

Panelists discuss how switching to a biologic with a different mechanism of action can enhance clinical outcomes in patients with inadequate responses to tumor necrosis factor inhibitors.

Shapiro spoke in his Maui Derm NP+PA Fall conference interview about differentiating between types of alopecia areata and about the potential use of JAK inhibitors.

The model Revised REACH-B outperforms an earlier model by incorporating predictors of predictors of age, sex, platelet count, ALT levels, and positive hepatitis B antigen result.

The FDA declined to approve the NDA for tradipitant for the treatment of symptoms of gastroparesis, suggesting that Vanda conduct additional studies.

High-risk SAFE scores were linked to increased mortality, especially in participants with alcohol-associated liver disease, as this group demonstrated the worst survival.

There were also no significant differences in clinical parameters at baseline for patients initiating first-line or not first-line therapy.

Ferric carboxymaltose achieved superior outcomes to an oral iron tablet for the treatment of anemia in pregnant women.

Zirwas described several highlights from his presentation on updates in managing atopic dermatitis, describing examples such as lebrikizumab and nemolizumab.

A key opinion leader discusses off-label treatments for fibromyalgia symptom management and promising ongoing studies, as well as mobile applications that can aid in monitoring and managing fibromyalgia symptoms.

Inpatients receiving brief cognitive behavioral therapy had a 60% reduced likelihood of suicide attempts and a 71% reduced rate of psychiatric readmissions post-discharge.

The new guidance reviews existing tools for weight management and provides recommendations for their use in clinical practice in patients with obesity and kidney disease.

Amanda Wilson, PhD, details how her team is developing risk assessment models to evaluate viral infection intervention in schools.

In her Maui Derm NP+PA Fall interview, Harper highlighted treatment approaches and unmet needs of patients with acne.

Georgios Kitsios, MD, PhD, discusses his team's interim results an analysis that is providing insights into the microbiome dynamics of critically ill patients with VAP.

Kerri Aronson, MD, MS, describes her team's research efforts to create educational resources that address the profound lack of patient knowledge around HP.

Roy Morello, MD, discusses his team's research into the causes of poor pulmonary function among patients with osteogenesis imperfecta—better known as "brittle bone disease."

In her Maui Derm NP+PA Fall conference presentation, Baldwin highlighted the latest information on approaches to treating rosacea.

After his review on recent literature, Zirwas’s Maui Derm NP+PA Fall interview featured a discussion about the biggest unmet needs among patients.

All patients had persistent tumor responses, with 2 complete responses and 1 case of stable disease.

The IL-23 inhibitor lowered the risk of uveitis more than TNF-α inhibitors in patients with moderate to severe psoriasis.

Announced on September 18, 2024, the approval of benralizumab for adults with EGPA, which is based on the MANDARA trial, marks the second FDA approval for EGPA.

The FDA has approved the Eversense 365, the world’s first 1-year continuous glucose monitor, with US availability expected in late 2024.